Literature DB >> 19541770

The alpha-galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain.

Michelle C Miller1, Anatole Klyosov, Kevin H Mayo.   

Abstract

Galectins are a sub-family of lectins, defined by their highly conserved beta-sandwich structures and ability to bind to beta-galactosides, like Gal beta1-4 Glc (lactose). Here, we used (15)N-(1)H HSQC and pulse field gradient (PFG) NMR spectroscopy to demonstrate that galectin-1 (gal-1) binds to the relatively large galactomannan Davanat, whose backbone is composed of beta1-4-linked d-mannopyranosyl units to which single d-galactopyranosyl residues are periodically attached via alpha1-6 linkage (weight-average MW of 59 kDa). The Davanat binding domain covers a relatively large area on the surface of gal-1 that runs across the dimer interface primarily on that side of the protein opposite to the lactose binding site. Our data show that gal-1 binds Davanat with an apparent equilibrium dissociation constant (K(d)) of 10 x 10(-6) M, compared to 260 x 10(-6) M for lactose, and a stiochiometry of about 3 to 6 gal-1 molecules per Davanat molecule. Mannan also interacts at the same galactomannan binding domain on gal-1, but with at least 10-fold lower avidity, supporting the role of galactose units in Davanat for relatively strong binding to gal-1. We also found that the beta-galactoside binding domain remains accessible in the gal-1/Davanat complex, as lactose can still bind with no apparent loss in affinity. In addition, gal-1 binding to Davanat also modifies the supermolecular structure of the galactomannan and appears to reduce its hydrodynamic radius and disrupt inter-glycan interactions thereby reducing glycan-mediated solution viscosity. Overall, our findings contribute to understanding gal-1-carbohydrate interactions and provide insight into gal-1 function with potentially significant biological consequences.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19541770      PMCID: PMC2720280          DOI: 10.1093/glycob/cwp084

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  45 in total

1.  On the galactosyl distribution of commercial galactomannans.

Authors:  P J Daas; H A Schols; H H de Jongh
Journal:  Carbohydr Res       Date:  2000-11-17       Impact factor: 2.104

Review 2.  Clusters, bundles, arrays and lattices: novel mechanisms for lectin-saccharide-mediated cellular interactions.

Authors:  C Fred Brewer; M Carrie Miceli; Linda G Baum
Journal:  Curr Opin Struct Biol       Date:  2002-10       Impact factor: 6.809

3.  Structure and functional analysis of the fungal galectin CGL2.

Authors:  Piers J Walser; Peter W Haebel; Markus Künzler; David Sargent; Ursula Kües; Markus Aebi; Nenad Ban
Journal:  Structure       Date:  2004-04       Impact factor: 5.006

4.  Crosslinking of mammalian lectin (galectin-1) by complex biantennary saccharides.

Authors:  Y Bourne; B Bolgiano; D I Liao; G Strecker; P Cantau; O Herzberg; T Feizi; C Cambillau
Journal:  Nat Struct Biol       Date:  1994-12

5.  NMRPipe: a multidimensional spectral processing system based on UNIX pipes.

Authors:  F Delaglio; S Grzesiek; G W Vuister; G Zhu; J Pfeifer; A Bax
Journal:  J Biomol NMR       Date:  1995-11       Impact factor: 2.835

6.  Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1.

Authors:  K E Pace; C Lee; P L Stewart; L G Baum
Journal:  J Immunol       Date:  1999-10-01       Impact factor: 5.422

7.  Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes.

Authors:  N L Perillo; C H Uittenbogaart; J T Nguyen; L G Baum
Journal:  J Exp Med       Date:  1997-05-19       Impact factor: 14.307

8.  beta-1,2-linked oligomannosides from Candida albicans bind to a 32-kilodalton macrophage membrane protein homologous to the mammalian lectin galectin-3.

Authors:  C Fradin; D Poulain; T Jouault
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

9.  Visualization of galectin-3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer.

Authors:  Julie Nieminen; Atsushi Kuno; Jun Hirabayashi; Sachiko Sato
Journal:  J Biol Chem       Date:  2006-11-02       Impact factor: 5.157

10.  Using pulse field gradient NMR diffusion measurements to define molecular size distributions in glycan preparations.

Authors:  Michelle C Miller; Anatole Klyosov; David Platt; Kevin H Mayo
Journal:  Carbohydr Res       Date:  2009-04-17       Impact factor: 2.104

View more
  24 in total

1.  Binding of Toxoplasma gondii glycosylphosphatidylinositols to galectin-3 is required for their recognition by macrophages.

Authors:  Françoise Debierre-Grockiego; Sebastian Niehus; Bernadette Coddeville; Elisabeth Elass; Françoise Poirier; Ralf Weingart; Richard R Schmidt; Joël Mazurier; Yann Guérardel; Ralph T Schwarz
Journal:  J Biol Chem       Date:  2010-08-20       Impact factor: 5.157

2.  Intra- and intermolecular interactions of human galectin-3: assessment by full-assignment-based NMR.

Authors:  Hans Ippel; Michelle C Miller; Sabine Vértesy; Yi Zheng; F Javier Cañada; Dennis Suylen; Kimiko Umemoto; Cecilia Romanò; Tilman Hackeng; Guihua Tai; Hakon Leffler; Jürgen Kopitz; Sabine André; Dieter Kübler; Jesús Jiménez-Barbero; Stefan Oscarson; Hans-Joachim Gabius; Kevin H Mayo
Journal:  Glycobiology       Date:  2016-02-23       Impact factor: 4.313

3.  Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1.

Authors:  Ruud P M Dings; Nigam Kumar; Michelle C Miller; Melissa Loren; Huzaifa Rangwala; Thomas R Hoye; Kevin H Mayo
Journal:  J Pharmacol Exp Ther       Date:  2012-12-11       Impact factor: 4.030

4.  Binding of a Soluble meso-Tetraarylporphyrin to Human Galectin-7 Induces Oligomerization and Modulates Its Pro-Apoptotic Activity.

Authors:  Yossef López de Los Santos; David N Bernard; Philippe Egesborg; Myriam Létourneau; Clara Lafortune; Matthew J Cuneo; Agathe Urvoas; David Chatenet; Jean-Pierre Mahy; Yves St-Pierre; Rémy Ricoux; Nicolas Doucet
Journal:  Biochemistry       Date:  2020-11-24       Impact factor: 3.162

5.  Structural aspects of binding of α-linked digalactosides to human galectin-1.

Authors:  Michelle C Miller; João P Ribeiro; Virginia Roldós; Sonsoles Martín-Santamaría; F Javier Cañada; Irina A Nesmelova; Sabine André; Mabel Pang; Anatole A Klyosov; Linda G Baum; Jesús Jiménez-Barbero; Hans-Joachim Gabius; Kevin H Mayo
Journal:  Glycobiology       Date:  2011-06-28       Impact factor: 4.313

6.  Structural features for α-galactomannan binding to galectin-1.

Authors:  Michelle C Miller; Anatole A Klyosov; Kevin H Mayo
Journal:  Glycobiology       Date:  2011-12-07       Impact factor: 4.313

7.  Binding of polysaccharides to human galectin-3 at a noncanonical site in its carbohydrate recognition domain.

Authors:  Michelle C Miller; Hans Ippel; Dennis Suylen; Anatole A Klyosov; Peter G Traber; Tilman Hackeng; Kevin H Mayo
Journal:  Glycobiology       Date:  2016-01       Impact factor: 4.313

8.  Novel polysaccharide binding to the N-terminal tail of galectin-3 is likely modulated by proline isomerization.

Authors:  Michelle C Miller; Y Zheng; Jingmin Yan; Yifa Zhou; Guihua Tai; Kevin H Mayo
Journal:  Glycobiology       Date:  2017-11-01       Impact factor: 4.313

Review 9.  Glycosylation Changes in Brain Cancer.

Authors:  Lucas Veillon; Christina Fakih; Hadi Abou-El-Hassan; Firas Kobeissy; Yehia Mechref
Journal:  ACS Chem Neurosci       Date:  2017-11-07       Impact factor: 4.418

10.  Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.

Authors:  P Storti; V Marchica; I Airoldi; G Donofrio; E Fiorini; V Ferri; D Guasco; K Todoerti; R Silbermann; J L Anderson; W Zhao; L Agnelli; M Bolzoni; E Martella; C Mancini; N Campanini; D M Noonan; P G Petronini; A Neri; F Aversa; G D Roodman; N Giuliani
Journal:  Leukemia       Date:  2016-05-20       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.